問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Tri-Service General Hospital (在職)

Division of Infectious Disease

Division of Infectious Disease

Division of Infectious Disease

Division of General Internal Medicine

更新時間：2023-09-19

張峰義
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

4Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

張峰義

List

9Cases

2023-11-01 - 2024-12-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2023-03-10 - 2024-11-14

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

2023-10-02 - 2030-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2023-05-01 - 2025-08-31

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2004-07-01 - 2005-12-01

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2021-01-30 - 2022-03-31

Phase II

A phase II,Placebo-controlled, Randomized, Observer-blind Study to Evaluate the Immunogenicity, Safety and Tolerability of UB-612 Vaccine against COVID-19 in Adolescent, Younger and Elderly Adult Volunteers

  • Condition/Disease

    COVID-19

  • Test Drug

    UB-612

Participate Sites
12Sites

Recruiting1Sites

Terminated11Sites

2008-06-01 - 2008-10-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2009-09-15 - 2010-06-30

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2015-06-30 - 2017-12-31

Phase IV

A post marketing surveillance study of Lipo-AB® (amphotericin B) in neutropenic patients with persistent fever

  • Condition/Disease

    neutropenic

  • Test Drug

    amphotericin B

Participate Sites
10Sites

Terminated9Sites

李文生
Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Infectious Disease

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB